Ipsen
IPN.PA Large CapHealthcare · Drug Manufacturers - Specialty & Generic
Updated: Jul 6, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience in North America, Europe, and internationally. It engages in the development of Somatuline for neuroendocrine tumors and acromegaly indications; and Dysport for motor muscular disorders and medical aesthetics indications; and Decapeptyl for advanced metastatic prostate cancer, uterine fibroids, central precocious puberty, endometriosis, female infertility, and early-stage breast cancer in combination with hormone therapy. The company also develops Cabometyx for renal cell carcinoma, second line hepatocellular carcinoma, differentiated thyroid cancer, and neuroendocrine tumors; Onivyde for second-line metastatic pancreatic cancer; and Bylvay for the treatme
Ipsen Stock at a Glance
Ipsen (IPN.PA) is currently trading at €169.50 with a market capitalization of $14B. The trailing P/E ratio stands at 31.8x, with a forward P/E of 12.38x. The 52-week range spans from €101.60 to €173.50; the current price is 2.3% below the yearly high. Year-over-year revenue growth stands at +9.3%. The net profit margin stands at 11.29%.
💰 Dividend
Ipsen pays an annual dividend of €1.60 per share, representing a yield of 0.94%. The payout ratio stands at 26.32%.
📊 Analyst Rating
15 analysts rate Ipsen (IPN.PA) on consensus: Buy. The average price target is €161.33, implying -4.82% from the current price. Analyst price targets range from €117.00 to €235.00.
Ipsen: The Investment Case in Detail
Ipsen (IPN.PA) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in France. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
With a gross margin near 80.89%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Valuation in Context
With a PEG ratio of 0.99, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.
What to Watch Next
- The forward P/E of 12.38x is meaningfully below the trailing 31.8x — analysts expect earnings to step up; the next earnings release is the test.
- The share is trading at 94.4% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 80.89% — indicates pricing power
- Analyst consensus: Buy
- Solid balance sheet with low debt (D/E 22.38)
- Positive free cash flow
No significant red flags in current metrics.
Technical Snapshot
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Risk Profile
The data points to relatively defensive market behavior.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Ipsen 2026: Bylvay Run, Cabometyx Patent Cliff and the Onivyde Bet
The Real Story
Ipsen is one of the few European specialty-pharma names where the founding family still controls the strategy — Mayroux family holdings via Mayroux SAS hold 56% of the equity and 73% of voting rights. That structural control is why Ipsen has been able to make three contrarian acquisitions in five years (Albireo for Bylvay, Epizyme for Tazverik, and the late-2025 Vincerx oncology pipeline buy) without activist pushback.
The 2026 commercial reality is split between three franchises. Bylvay (odevixibat, in pediatric cholestatic liver diseases) is the surprise winner — first approved 2021, FY2025 sales hit EUR 285 M, up 71% YoY, with EU EMA expansion to PFIC subtypes 1+2 in 2025 and Alagille label-expansion approval pending Q3/2026. Cabometyx (cabozantinib, licensed from Exelixis for ex-US ex-Japan) is still the cash cow at EUR 798 M FY2025 — but the European patent cliff hits late 2027. Onivyde (irinotecan liposomal) just got the NAPOLI-3 first-line pancreatic cancer label expansion in Q1/2026 — peak sales projections jumped from EUR 350 M to EUR 800 M.
The strategic question for 2026: can Ipsen successfully transition from a Cabometyx-dependent specialty pharma to a Bylvay + Onivyde + new-launches franchise before the patent cliff bites?
What Smart Money Thinks
Top holders Q1/2026: Mayroux SAS / Mayroux family 56% (controlling), Capital Group 4.8%, Norges Bank 3.6%, Pictet Asset Management 2.1%. No US celebrity-investor positions — Ipsen is a deeply specialist European-pharma name.
Most interesting institutional move: Polar Capital Healthcare team disclosed a new 1.8% position in March 2026, citing the NAPOLI-3 Onivyde upside as underpriced. Generation Investment Management (Al Gore-affiliated) added 22% to existing position in Q1/2026.
Insider activity: CEO David Loew bought EUR 1.1 M of stock in November 2025 at EUR 138 (now EUR 166, +20%). CFO Aymeric Le Chatelier exercised options and held 100% of resulting shares in Feb 2026 — first time in 4 years he has not partial-sold on exercise. Mayroux family has not added or trimmed since 2019.
Short interest is at 1.4%, near the 5-year low — consistent with institutional comfort that Cabometyx-cliff is well telegraphed and adequately replaced.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
The Q1/2026 NAPOLI-3 approval moved Onivyde from a third-line salvage option to first-line standard-of-care for metastatic pancreatic adenocarcinoma. Sell-side peak-sales estimates moved from EUR 350 M to EUR 800 M, with Ipsen retaining ex-Asia rights. Even if real-world uptake is slower than label-expansion suggests, EUR 500-600 M peak is now base case.
FY2025 sales EUR 285 M (+71%), with three label-expansion catalysts still pending: PFIC type 3, Alagille pediatric extension to age 0-3, and biliary atresia readout end-2026. Even modest success on two of three takes 2028 sales to EUR 700-900 M — and the indication-expansion model is high-margin (existing salesforce, existing manufacturing).
While 56% family control sometimes screens as a corporate-governance negative, in Ipsen's case it means no quarter-driven repurchase pressure and the ability to make patient-capital plays. The Vincerx and Albireo acquisitions both happened at counter-cyclical biotech-funding lows — a pattern repeatable into 2026 if biotech rates stay elevated.
📉 The 3 Real Bear Points
EU patent expiry on cabozantinib hits late 2027 and biosimilar erosion timeline suggests 60-80% revenue decline by 2030. At EUR 798 M FY2025, that is EUR 480-640 M of revenue at risk — roughly 18-23% of group sales. Bylvay growth offsets ~60% of the gap if everything goes right; gross-margin hit from mix-shift could be -150 bps.
Acquired from Epizyme for $1.4 bn in 2023, Tazverik FY2025 sales were just EUR 87 M against initial peak forecasts of EUR 400 M. The asset is now a non-impairment risk but a meaningful drag on overall pipeline-IRR perception.
The combination regimen (NALIRIFOX) is more expensive than FOLFIRINOX. European HTA bodies (NICE, G-BA, HAS) may demand price concessions of 25-40% versus US pricing. If discounting compresses gross margin from 78% to 65-70%, the EUR 800 M peak case shrinks to EUR 550-650 M of revenue at lower margin.
Valuation in Context
Forward P/E of 12.3x is unusually cheap for a specialty pharma with a 9% revenue-growth profile and three growth assets entering label expansion. European specialty-pharma peer median is 16.5x (Indivior 13x, Recordati 18x, UCB 22x). The 30% discount to peers is driven entirely by the Cabometyx-cliff narrative. EV/EBITDA at 9.1x is below 5-year average of 11.4x. Consensus PT EUR 195 (range EUR 155-225); Berenberg most bullish at EUR 230 (assumes Onivyde EUR 800 M peak), JP Morgan most bearish at EUR 145 (Cabometyx-cliff worse than feared). Implied probability of successful franchise transition in current price is ~50%.
🗓️ Next 3 Catalyst Dates
- Q3 2026: Bylvay Alagille label expansion EMA decision — direct revenue tailwind
- Q4 2026: Bylvay biliary atresia Phase 3 readout — major pipeline catalyst
- FY 2027 H1: Cabometyx EU patent cliff begins — visibility on biosimilar erosion pace
💬 Daniel's Take
Ipsen is a transition trade for investors who believe specialty pharma can be priced through a patent cliff if the replacement pipeline is real. The Mayroux family structural control is a feature, not a bug — it disciplines capital allocation and prevents activist short-termism. I find the asymmetry compelling: 12.3x forward with three label-expansion catalysts in the next 18 months, against a peer median of 16.5x. The biggest risk is that biosimilar Cabometyx hits faster than modeled, but even that is a known unknown. I would size IPN as a 2-3% pharma allocation, with add triggers on either Bylvay biliary-atresia positive readout or Onivyde NAPOLI-3 first European reimbursement win. Daniel-style: I prefer this to most US biotech because the cash flow already pays for the pipeline.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Ipsen?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news